Skip to main content
. Author manuscript; available in PMC: 2022 Nov 1.
Published in final edited form as: Ann Oncol. 2021 Aug 11;32(11):1425–1433. doi: 10.1016/j.annonc.2021.08.1746

Figure 1. Biomarker diagnostic utility.

Figure 1.

1A. Cohort 1 (n=2,415): NETest scores (y-axis) and the percentage positive cases (x-axis) irrespective of disease status (includes CR/NED) for the principal organ sites. Upper limit of normal=20 is expressed by the red dotted line. The majority of NETs (>80%) exhibit an elevated NETest with mean scores >20.

1B. Cohort 2 (n=1,270): Relationship between the percentage positive cases and the calculated relative risk (versus the controls, benign and malignant diseases: n=348) for the principal sites. NETest (red circles) and CgA (blue circles). Pancreatic (P), small bowel (SB), CUP and lung (BP – bronchopulmonary) exhibited relative risks of >3 for the NETest. CgA exhibited lower performance metrics especially for rectal (R), lung (BP) and pancreatic (P) NETs (all with <40% positive samples, RR<1.5). Dotted lines reflect a 50% cut-off for test positive (horizontal line) and a RR of 1.0 (vertical line).

BD = Benign disease. BP = bronchopulmonary (lung). CON = control. CR = complete remission. CUP = carcinoid of unknown primary. G = gastric. IVD = in vitro diagnostic. NED = no evidence of disease. NEO = other neoplasia. P = pancreatic. R = rectal. SB = small bowel.